Please ensure Javascript is enabled for purposes of website accessibility

Got $3,000? Buying These 3 Stocks Could Make You Rich

By Keith Speights - Updated Sep 4, 2020 at 11:47AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

All you have to do is buy -- and wait.

How do you make a lot of money in the stock market? One way is to start out with a lot of money to invest. You've no doubt heard that it takes money to make money. Another way to do it is to have a long investing horizon. Many stocks will generate pretty good returns, given enough time. 

But what if you only have a relatively small amount of money to invest and can't let your investments ride for 40 years? The best strategy is to pick stocks with tremendous growth prospects. If you've got $3,000 to invest, buying these three stocks could make you rich without having to wait most of your lifetime.

Light bulb over a woman's palm and a dollar sign made up of money over a man's palm

Image source: Getty Images.

1. MongoDB

Humongous. The middle of that word is where MongoDB (MDB -3.04%) gets its name. And it's a great description of the potential for the company and its database platform.

Data makes modern life possible. Every app you use, every text you send, every streaming TV show you watch -- they all rely on data. That data must be stored and accessed. But most of the databases with leading market shares were designed decades ago for nice, orderly data. Today's data -- audio, images, videos, unstructured text -- isn't so nice and orderly.

MongoDB's database platform was built from the ground up for today's kind of data. It was also designed to run anywhere, including the cloud (where most apps and data are flocking). The company's revenue continues to soar, with 39% year-over-year sales growth in the second quarter.

The biggest knocks against MongoDB are that it's not profitable yet and its valuation is steep, with shares trading at nearly 28 times sales. But it's only a matter of time before the company reaches profitability with its subscription-based model. And the stock is cheaper than it looks when you consider MongoDB's fantastic growth prospects. MongoDB's shares are up more than 80% so far this year and still have a big -- no, a humongous -- runway ahead.

2. The Trade Desk

How many streaming TV services can you name? Probably not all of them. There are more than 200 streaming TV services available. Many of them present fertile ground for The Trade Desk (TTD -3.57%).

The company ranks as the leader in buy-side programmatic advertising. Programmatic advertising, by the way, uses software to buy and sell ads instead of person-to-person negotiations and is taking the ad world by storm. Connected TV (CTV), which includes those 200+ streaming TV services, also presents a game-changer for advertisers.

Yes, the COVID-19 pandemic weighed on The Trade Desk's growth in the first half of 2020. But the company still beat expectations in Q2 and expects a return to strong growth in Q3.

The coronavirus outbreak could even improve The Trade Desk's long-term growth story. CEO Jeff Green said in the company's Q2 conference call, "We believe the COVID pandemic has permanently accelerated the growth of connected television, changing the TV landscape forever." With CTV growing, The Trade Desk stock should keep up its remarkable momentum for years to come.

3. Vertex Pharmaceuticals

You'll have a hard time finding a better biotech stock than Vertex Pharmaceuticals (VRTX -1.22%). Why? It enjoys a virtual monopoly. It has tremendous near-term growth prospects, and its pipeline holds the potential to drastically expand its market.

That virtual monopoly is in cystic fibrosis (CF). Vertex's four Food and Drug Administration (FDA)-approved drugs are the only ones that treat the underlying cause of CF. The company's newest CF drug, Trikafta/Kaftrio, was approved in the U.S. less than a year ago and is already a blockbuster. It also won European approval in August. Vertex's sales are primed to skyrocket as the biotech launches Kaftrio in key European markets.

But CF is only the beginning for Vertex. The company is evaluating two drugs in phase 2 clinical studies targeting alpha-1 antitrypsin deficiency (AATD). The rare genetic disease is similar to CF in that it's caused by protein folding issues. And there are more patients with AATD in the U.S. than there are CF patients in the entire world.

Vertex's pipeline also includes other programs targeting genetic diseases such as beta-thalassemia, sickle cell disease, and APOL1-mediated kidney diseases. In addition, the company hopes to advance a gene therapy candidate that could address the root cause of type 1 diabetes into an early stage clinical study next year.

Vertex already claims a market cap of over $70 billion. But given some time, this biotech could become a lot bigger -- and, like MongoDB and The Trade Desk, make investors rich in the process.

Keith Speights owns shares of MongoDB, The Trade Desk, and Vertex Pharmaceuticals. The Motley Fool owns shares of and recommends MongoDB and The Trade Desk. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$292.16 (-1.22%) $-3.61
The Trade Desk Stock Quote
The Trade Desk
$71.59 (-3.57%) $-2.65
MongoDB Stock Quote
$368.76 (-3.04%) $-11.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.